Pfizer Inc announced that the US Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee voted 10 to one that the data presented support the safety and effectiveness of its 13-valent pneumococcal conjugate candidate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for the prevention of invasive pneumococcal disease in infants and young children.
The details can be read here.
No comments:
Post a Comment